Navigation Links
Karmanos Cancer Institute Announces Interim Leadership
Date:3/5/2009

DETROIT, March 5 /PRNewswire-USNewswire/ -- The Barbara Ann Karmanos Cancer Institute and Karmanos Cancer Center boards of directors today announced that effective immediately Ann G. Schwartz, Ph.D. has been appointed Interim President and Chief Executive Officer, and Paul Broughton has been appointed Interim Chief Operating Officer.

(Logo: http://www.newscom.com/cgi-bin/prnh/20071106/KARMANOSLOGO )

"Dr. Schwartz is an excellent choice to lead us during this period of transition," said Alan S. Schwartz, Chair, Karmanos Cancer Institute Board of Directors. "As Interim President and Chief Executive Officer, Ann will focus on leading the Institute's scientific direction, while continuing our outstanding world-class research in basic, clinical and population sciences," noted Alan Schwartz.

Having rejoined the Karmanos faculty 10 years ago, Dr. Schwartz, who is unrelated to Alan Schwartz, has extensive experience and knowledge of the Institute.

Previous to this appointment, Dr. Schwartz served as the Associate Center Director for Population Sciences at Karmanos since 2002. Her research focuses on the genetics underlying lung cancer risk. She has an M.S. in Biology from Wayne State University, an M.P.H. in Environmental Health from the University of Michigan, and a Ph.D. in Epidemiology from the University of Michigan School of Public Health.

Dr. Schwartz' first faculty appointment was with the Michigan Cancer Foundation in 1986. She spent 1991-1999 at the University of Pittsburgh and the MCP-Hahnemann School of Medicine. She returned to Karmanos in 1999. Dr. Schwartz has been the recipient of continuous grant support from the National Institutes of Health for more than 20 years.

As Interim Chief Operating Officer, Broughton's main responsibilities include the smooth and efficient operation of the Karmanos Cancer Center to ensure the delivery of high quality care at the hospital and all of the Karmanos clinical operations while continuing their profitability.

Broughton served on both Karmanos boards through December 2007 and was a member of the Institute's Finance and Compensation committees. Prior to his retirement, he was President and Chief Executive Officer of Harper Hospital and Children's Hospital of Michigan.

He is also a Fellow in the American College of Healthcare Executives and a Fellow in the Hospital Financial Management Association.

"Ann will work directly with Paul Broughton, our Interim Chief Operating Officer, to continue our excellence in clinical care for our patients. Both Ann and Paul have extensive knowledge and understanding of our commitment to patient care and cancer research," said Alan Schwartz.

"I am delighted that Ann Schwartz was named interim chief executive officer of the Karmanos Cancer Institute," said Wayne State University President Jay Noren. "As an experienced researcher and administrator, Dr. Schwartz will be a significant asset for the Institute as it continues to fulfill and expand its role as one of the nation's preeminent cancer research and treatment centers."

"The faculty and staff of the Wayne State University School of Medicine are looking forward to working closely with Dr. Schwartz as she assumes leadership of the Karmanos Cancer Institute," said Robert Mentzer, M.D., dean of the Wayne State University School of Medicine. "The medical school and the Institute have a tradition of cooperation in medical research, patient care and teaching that has become a model for medical institutions across the country."

"I have worked with Ann for more than six years. She is an exemplary researcher who is dedicated to finding a cure for this insidious disease. She is a strong leader and will serve the Institute well during this transition," said John C. Ruckdeschel, M.D., the outgoing president and CEO of the Karmanos Cancer Institute.

Karmanos board leadership has worked closely with Wayne State University and its School of Medicine throughout the process of naming an interim leader and will continue to do so as they engage in a nationwide search for the permanent position.

About The Barbara Ann Karmanos Cancer Institute

Located in mid-town Detroit, MI, the Barbara Ann Karmanos Cancer Institute is one of 40 National Cancer Institute-designated comprehensive cancer centers in the United States. Caring for more than 6,000 new patients annually on a budget of $216 million, conducting more than 700 cancer-specific scientific investigation programs and clinical trials, the Karmanos Cancer Institute is among the nation's best cancer centers. Through the commitment of 1,000 staff, including nearly 300 faculty members, and supported by thousands of volunteer and financial donors, the Institute strives to prevent, detect and eradicate all forms of cancer. For more information call 1-800-KARMANOS or go to www.karmanos.org.


'/>"/>
SOURCE Barbara Ann Karmanos Cancer Institute
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Susan G. Komen for the Cure, Karmanos Cancer Institute, Community Leaders, Breast Cancer Survivors and Activists to Gather at Forum and Call for Action on Breast Cancer
2. Susan G. Komen For The Cure, Karmanos Cancer Institute, Local Hospitals Call on Policymakers to Address Injustice and Unfairness in Breast Cancer Incidence and Mortality
3. Karmanos Cancer Center Most Preferred Hospital for Cancer Care According to 2007 Survey
4. Danialle Karmanos Work It Out Launches Dynamic Blog
5. Kroger Pink Tag Campaign Raises $137,500 for Breast Cancer Research and Awareness at Karmanos Cancer Institute
6. Nominations for Outstanding Cancer Survivor Award Being Accepted by Karmanos Cancer Institute Through April 27
7. McCarty Cancer Foundation Awards $50,000 Grant for Myeloma Research Program at Karmanos Cancer Institute
8. Karmanos Researchers Report Enhanced Chemosensitivity of Pancreatic Cancer Cells by Black Seed Component
9. Karmanos Cancer Center Partners With Meadowbrook to Expand Outreach and Access for Cancer Services
10. J.P. McCarthy Fund Grants $250,000 to Karmanos Cancer Institute
11. Karmanos Cancer Center Most Preferred Hospital for Cancer Care in Southeast Michigan
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/25/2016)... Austin, TX (PRWEB) , ... June 25, 2016 , ... ... Fellow of the American College of Mohs Surgery and to Dr. Russell Peckham for ... popular and highly effective treatment for skin cancer. The selective fellowship in Mohs Micrographic ...
(Date:6/25/2016)... ... 25, 2016 , ... As a lifelong Southern Californian, Dr. Omkar Marathe earned ... the David Geffen School of Medicine at UCLA. He trained in Internal Medicine at ... fellowship in hematology/oncology at the UCLA-Olive View-Cedars Sinai program where he had the opportunity ...
(Date:6/24/2016)... ... June 24, 2016 , ... A recent article ... people are unfamiliar with. The article goes on to state that individuals are now ... of these less common operations such as calf and cheek reduction. The Los Angeles ...
(Date:6/24/2016)... Dallas, Texas (PRWEB) , ... June 24, 2016 ... ... 12th International Conference and Scientific Sessions in Dallas that it will receive two ... Announcement of the grants came as PHA marked its 25th anniversary by recognizing ...
(Date:6/24/2016)... ... 24, 2016 , ... Topical BioMedics, Inc, makers of Topricin and MyPainAway Pain Relief Products, join ... wage raise to $12 an hour by 2020 and then adjusting it yearly to increase ... of the minimum wage, assure the wage floor does not erode again, and make future ...
Breaking Medicine News(10 mins):
(Date:6/26/2016)...  VMS Rehab Systems, Inc. ( www.vmsrehabsystemsinc.com ) reported ... required to build a strong and stable market for ... on the OTC Markets-pink current trading platform. ... are seeing an anomaly in market trading activities that ... the Company, but shareholders and market players as well. ...
(Date:6/24/2016)... N.C. , June 24, 2016  Consumers ... decisions and regulators/payers have placed more emphasis on ... environment, patient support programs in the pharmaceutical industry ... patients, medications. Consequently, pharmaceutical companies are focusing on ... they are providing products and services that improve ...
(Date:6/24/2016)... SOUTH SAN FRANCISCO, Calif. , June 24, ... GBT ), a biopharmaceutical company developing novel ... with significant unmet needs, today announced the closing ... 6,400,000 shares of common stock, at the public ... the shares in the offering were offered by ...
Breaking Medicine Technology: